Research
Early treatment for eosinophilic esophagitis may lower children's asthma risk
The Brief
- A new study presented at the American College of Allergy, Asthma and Immunology found that young children treated for eosinophilic esophagitis (EoE) with dupilumab were less likely to develop asthma later.
- The comparison group received a different treatment for EoE.
- The source reports these findings from a single presented study.
Why it matters
The findings suggest the choice of EoE treatment in early childhood may affect later asthma risk, which could matter when clinicians weigh treatment options for young patients.
Who’s affected
- clinicians treating children with eosinophilic esophagitis
- parents of young children with eosinophilic esophagitis
- allergy and asthma specialists
- #allergy
- #asthma
- #eosinophilic esophagitis
- #dupilumab
- #pediatrics
Young children treated for eosinophilic esophagitis (EoE) with dupilumab were less likely to develop asthma in the future compared with children who received a different treatment. The findings come from a new study presented at the American College of Allergy, Asthma and…